Company intelligence / Profile preview

Lung Therapeutics

Austin, Texas, United Stateslungtx.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Lung Therapeutics developed a pipeline of novel therapies targeting life-threatening and underserved lung conditions, with a focus on fibrotic diseases. Its lead asset LTI‑03 targets idiopathic pulmonary fibrosis and was in Phase 1b clinical trials at the time of acquisition. Another key candidate, LTI‑01, addresses loculated pleural effusion. The company was acquired by Aileron Therapeutics in October 2023 to further advance these programs.

Therapeutic areas: PulmonologyRare Diseases
Modalities: Biological products (e.g., peptides)Plasminogen activatorsCAV1 modulators
Industry: Biotech

Drug pipeline

2 assets

LTI-03

Phase 1

Indications: Idiopathic pulmonary fibrosis

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Lung Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lung Therapeutics.

Explore the full profile